DZ BANK AG acted as sole financial advisor to LEO in the sale of Lomapharm to DAICEL Corporation

LOMAPHARM is an international active specialized Contract Manufacturing and Development Organization (CDMO) of pharmaceutical and health supplemental products. The product portfolio comprises film-coated tablets, sugar coated tablets, (sterile) eye and nasal sprays as well as nutritional supplements. LOMAPHARM serves international customers in the pharma segment and NGOs. DUBAG acquired LOMAPHARM in 2014 during a competitive auction process led by DZCF and developed the target further until 2018. Revenue growth was about 25% and the number of employees slightly increased to approx. 150. DAICEL is an internationally operating chemical company based in Osaka, Japan and entered the European CDMO market via the acquisition of LOMAPHARM.

DZ BANK AG Corporate Finance advised LEO, a private equity investor in the DACH region on the sale of its portfolio company.


Advised in the sale of

LOMA Holding GmbH (Lomapharm)


Daicel Corporation


MidCap Alliance